Navigation Links
Keystone Nano Announces Progress On RNA Delivery
Date:4/11/2017

STATE COLLEGE, Pa., April 11, 2017 /PRNewswire/ -- Keystone Nano, Inc. (KN), a clinical stage biopharmaceutical company focused on improving cancer treatments through the application of nanotechnology, announced today significant progress on the delivery of RNA using NanoJackets (NJs).  KN's NanoJackets are proprietary, customizable calcium phosphate nanoparticles that protect the active agent in the bloodstream and deliver it to targeted cells.  Key recent achievements include:

  • substantial new knowledge on encapsulating various kinds of RNA including siRNA, micro RNA and messenger RNA,
  • improved knowledge about the safety/toxicity of the NanoJacketed RNA,
  • new understanding of bio-distribution after administration by injection or inhalation, and
  • greater knowledge about the length of time RNA-NanoJackets work within the body

KN is working to optimize the therapeutic activity of RNA both for the internal programs and for pharmaceutical client companies.  KN has found that working with NanoJackets to encapsulate and deliver the different types of RNA requires different approaches for each.  However, in all cases, KN's RNA-NanoJackets have shown that they contain substantial amounts of RNA, are composed of safe and well tolerated materials, protect the RNA from degradation in the blood stream and can be targeted to specific cell types.

Several new breakthrough therapies anticipate using the different types of RNA to halt disease progression – either by silencing select RNA processes associated with disease, or by using RNA to code for production of therapeutic molecules within the body itself.  The increasing interest in RNA therapy has led to a need for a safe, effective and efficient method to deliver RNA.  KN's calcium phosphate NanoJackets offer a highly biocompatible, non-toxic and effective solution to that problem.

KN's work in RNA delivery has been supported by grants from the National Cancer Institute, the National Institute for Allergies and Infectious Diseases, and the Pennsylvania Department of Health.  KN's work in RNA delivery builds on work at Penn State and the University of Virginia. Jeff Davidson, KN's CEO, noted: "our research team has made great progress building powerful new ways to deliver RNA.  Our goal is to continue this work to further improve human health."

About Keystone Nano, Inc.  KNs lead product, Ceramide NanoLiposome, entered clinical testing in early 2017.  For more information visit www.keystonenano.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/keystone-nano-announces-progress-on-rna-delivery-300437963.html


'/>"/>
SOURCE Keystone Nano, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer
2. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
3. MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering
4. University City Keystone Innovation Zone Expands to Old City, N3rd Street Startup Community
5. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
6. Greater Gift Initiative Announces Partnership with INC Research
7. Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares
8. Bioptix Announces Executive Leadership Change
9. Nerium International announces expansion into New Zealand
10. Charm Sciences Announces New Sales/Business Manager
11. BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... 21, 2017 , ... Today, BioPharma Institute, a leading training ... of 5 new courses to its prospectus. These include the eagerly-awaited Regulation ... 11 on Electronic Records and Electronic Signatures (Part 11 of Title 21 of ...
(Date:9/20/2017)... ... 2017 , ... The award-winning producers behind the American Farmer ... innovations aimed at helping farmers solve the problem of nitrogen loss. The upcoming ... 8:30aET on RFD-TV. Check your local listings for more info. , As ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... pathology, and Huron Digital Pathology , a provider of whole slide imaging ... Pathology Visions conference . The workshop, entitled “Successfully Deploying a Best-in-Class Strategy for ...
(Date:9/20/2017)... ... September 20, 2017 , ... RoviSys, a leading independent ... the opening of an office in Taipei, Taiwan. This new location allows RoviSys ... developing new relationships in the region. Located in the Neihu area of Taipei, ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):